Reaffirmed: Inovio Pharmaceuticals (NASDAQ:INO) “Buy” Rating Reconfirmed by Analysts at H.C. Wainwright; $13.0000 Target in Place

May 16, 2018 - By Adrian Erickson

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Logo

Inovio Pharmaceuticals (NASDAQ:INO) Rating Reaffirmed

They currently have a $13.0000 PT on Inovio Pharmaceuticals (NASDAQ:INO). The target price by H.C. Wainwright would suggest a potential upside of 154.90 % from the company’s previous stock close. This has been revealed to clients and investors in a research note on Wednesday morning.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Ratings Coverage

Among 2 analysts covering Inovio Pharmaceuticals (NASDAQ:INO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Inovio Pharmaceuticals has $14.0 highest and $1300 lowest target. $13.50’s average target is 164.71% above currents $5.1 stock price. Inovio Pharmaceuticals had 9 analyst reports since November 28, 2017 according to SRatingsIntel. As per Thursday, March 15, the company rating was maintained by H.C. Wainwright. The firm has “Buy” rating given on Friday, January 12 by H.C. Wainwright. H.C. Wainwright maintained Inovio Pharmaceuticals, Inc. (NASDAQ:INO) on Tuesday, February 13 with “Buy” rating. H.C. Wainwright maintained Inovio Pharmaceuticals, Inc. (NASDAQ:INO) on Tuesday, January 23 with “Buy” rating. On Wednesday, January 3 the stock rating was maintained by H.C. Wainwright with “Buy”. The rating was maintained by H.C. Wainwright on Tuesday, November 28 with “Buy”. The stock of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) earned “Buy” rating by H.C. Wainwright on Wednesday, March 21. H.C. Wainwright maintained the stock with “Buy” rating in Thursday, April 12 report. The stock of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has “Buy” rating given on Thursday, March 15 by RBC Capital Markets.

The stock increased 2.00% or $0.1 during the last trading session, reaching $5.1. About 1.45M shares traded or 42.63% up from the average. Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has declined 24.44% since May 17, 2017 and is downtrending. It has underperformed by 35.99% the S&P500.

Analysts await Inovio Pharmaceuticals, Inc. (NASDAQ:INO) to report earnings on August, 14. They expect $-0.28 earnings per share, down 115.38 % or $0.15 from last year’s $-0.13 per share. After $-0.36 actual earnings per share reported by Inovio Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -22.22 % EPS growth.

Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. The company has market cap of $463.91 million. The Company’s SynCon immunotherapy design has the ability to break the immune systemÂ’s tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It currently has negative earnings. It has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, Ebola, Middle East Respiratory Syndrome, and Zika virus.

More important recent Inovio Pharmaceuticals, Inc. (NASDAQ:INO) news were published by: which released: “Inovio Pharma (INO) Says HIV Vaccine Sustained Durable Memory Responses Measured One Year After Start of …” on May 15, 2018, also published article titled: “Inovio Stock Buzzing After HIV Vaccine Data”, published: “Inovio HIV Vaccine, Which Generated Near 100% Immune Responses, Sustained Durable Memory Responses …” on May 15, 2018. More interesting news about Inovio Pharmaceuticals, Inc. (NASDAQ:INO) was released by: and their article: “Inovio Pharmaceuticals Reports 2018 First Quarter Financial Results” with publication date: May 09, 2018.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.